Boston Scien Cp SEC Filings

Boston Scientific filed an 8-K to share landmark clinical data for two cardiovascular therapies. The HI-PEITHO randomized trial in 544 patients with intermediate-risk pulmonary embolism showed the EKOS endovascular system plus anticoagulation was superior to anticoagulation alone on a composite endpoint (4.0% vs. 10.3%; 61% relative reduction), without intracranial bleeding through 30 days and with shorter hospital stays.

The CHAMPION-AF trial in 3,000 patients with non-valvular atrial fibrillation found the WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and efficacy endpoints versus leading blood thinners over 36 months, delivering markedly lower non-procedural bleeding (10.9% vs. 19.0%) and similar protection from stroke and cardiovascular death, with a 99% procedural success rate.

Boston Scientific Corp ownership disclosure: The Vanguard Group filed an amendment reporting that, after an internal realignment, it and certain subsidiaries will report beneficial ownership separately. The amendment states amount beneficially owned: 0 and percent of class: 0% as of the filing. The filing explains the disaggregation follows SEC Release No. 34-39538 and that subsidiaries pursue prior investment strategies.

Boston Scientific Corporation is asking stockholders to vote at a virtual 2026 Annual Meeting on April 30, 2026 at 8:00 a.m. Eastern Time. Holders of common stock at the close of business on March 6, 2026, when 1,486,175,167 shares were outstanding, may vote.

Stockholders are asked to elect ten directors, approve on an advisory basis the compensation of named executive officers, and ratify Ernst & Young LLP as independent auditor for the 2026 fiscal year. The Board recommends voting FOR all three items.

The agenda includes governance and capital proposals: amending the Employee Stock Purchase Plan to increase shares reserved; removing supermajority voting provisions; adding Delaware-permitted officer exculpation; and allowing stockholders holding 25% of common stock to call a special meeting. The Board supports these four proposals and recommends AGAINST a separate stockholder proposal titled “Give Shareholders the Ability to Call for a Special Shareholder Meeting.”

Boston Scientific Corporation is asking shareholders to vote at its virtual Annual Meeting on April 30, 2026 (virtual webcast at www.virtualshareholdermeeting.com/BSX2026) for holders of record as of March 6, 2026. The Board recommends FOR proposals 1–7 (including director elections, say‑on‑pay, accountant ratification, ESPP increase, and amendments to the Certificate of Incorporation and By‑Laws) and AGAINST the stockholder proposal to allow special meetings. The proxy materials describe Board refreshment: Cathy R. Smith and Christophe P. Weber joined the Board in February 2026, and John E. Sununu and Yoshiaki Fujimori will not stand for re‑election. Voting instructions, quorum rules, and voting methods (internet, phone, mail, virtual attendance) are provided in the proxy materials.

Boston Scientific director Cheryl Pegus reported an equity award in the form of deferred stock units. On March 2, 2026, she acquired 24 deferred stock units at a stated price of $0.00 per unit, reflecting $1,845.25 of compensation based on the common stock’s closing price that day.

Each deferred stock unit represents a commitment by Boston Scientific to issue one share of common stock in the future. These units were granted in lieu of 50% of her yearly cash compensation, vest in full at the next annual stockholder meeting, and the underlying shares will be delivered after she leaves the Board under the company’s non-employee director deferred compensation plan. Following this grant, her reported direct holdings total 5,917 deferred stock units.

Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director Susan E. Morano received an equity grant of 24 shares of common stock on March 2, 2026, at no cash cost to her. The award is restricted stock granted in lieu of 50% of her cash compensation, valued at $1,845.25 based on the closing share price on the grant date, and will vest in full at the next annual meeting of stockholders. Following this grant, she directly holds 6,663 Boston Scientific shares.

Boston Scientific director Christophe Pierre Weber reported receiving two restricted stock grants as a non-employee director. He acquired 556 shares of common stock as an initial equity award with an approximate value of $42,419.50, prorated under the company’s non-employee director compensation program.

Weber also received 323 restricted shares in lieu of 100% of his prorated yearly cash retainer, with an approximate value of $24,662.50. Both grants were based on the closing stock price on the grant date and are scheduled to vest in full at the company’s 2026 annual meeting of stockholders.

Boston Scientific director Cathy R. Smith received two grants of deferred stock units as part of her non-employee director compensation. She acquired 556 deferred stock units valued at approximately $42,419.50 as an equity award and 323 deferred stock units valued at approximately $24,662.50 in lieu of yearly cash compensation. Each deferred stock unit represents a commitment to issue one share of common stock. Both grants are prorated from her appointment date to the 2026 annual meeting and vest in full at the next annual meeting, with shares delivered after she leaves Board service under the company’s deferred compensation plan.

Boston Scientific (BSX) senior vice president Emily Woodworth reported equity compensation activity involving restricted stock units and common stock. On March 1, 2026, she exercised or converted 838 restricted stock units, which represent a commitment to issue one share of common stock for each unit.

The same day, she acquired 838 shares of Boston Scientific common stock through this derivative exercise. Also on March 1, 372 shares of common stock were disposed of at $76.85 per share in a transaction classified as payment of tax liability by delivering securities. After these transactions, she directly owned 1,676 restricted stock units and 2,859 common shares.

Boston Scientific discussed the strategic rationale and integration approach for its proposed acquisition of Penumbra during a TD Cowen conference Q&A on March 3, 2026. Executives said Penumbra would operate as a stand-alone global business unit within Boston Scientific’s cardiovascular/ICTx portfolio, retaining its commercial team and leadership. Management highlighted opportunities to scale Penumbra outside the U.S., leverage Boston Scientific’s supply chain (including Costa Rica manufacturing), and cross-sell complementary products across neurovascular, thrombectomy, vascular and interventional cardiology accounts. The transaction remains subject to regulatory review and customary closing conditions; Boston Scientific referenced a Form S-4/proxy filing in connection with the proposed transaction.

Boston Scientific discussed the strategic rationale and integration approach for its proposed acquisition of Penumbra during a TD Cowen conference Q&A on March 3, 2026. Executives said Penumbra would operate as a stand-alone global business unit within Boston Scientific’s cardiovascular/ICTx portfolio, retaining its commercial team and leadership. Management highlighted opportunities to scale Penumbra outside the U.S., leverage Boston Scientific’s supply chain (including Costa Rica manufacturing), and cross-sell complementary products across neurovascular, thrombectomy, vascular and interventional cardiology accounts. The transaction remains subject to regulatory review and customary closing conditions; Boston Scientific referenced a Form S-4/proxy filing in connection with the proposed transaction.